Imenor (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This reduces the proliferation of rapidly dividing cells, including immune cells and cancer cells, leading to immunosuppression and antiproliferative effects that are therapeutic in autoimmune diseases and malignancies.

The specific dose of Imenor is determined by the prescribing clinician based on the patient’s condition, disease severity, renal and hepatic function, and other individual factors. Dosage regimens vary widely, and the prescriber will tailor the amount and frequency to achieve optimal therapeutic effect while minimizing risk.

Methotrexate is classified as pregnancy category X because it is known to cause fetal harm and is contraindicated in pregnancy. It is also excreted in breast milk and may affect a nursing infant. Women of child‑bearing potential must use effective contraception and avoid the drug during pregnancy and lactation.

To request Imenor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Methotrexate is often considered a first‑line DMARD because of its proven efficacy, oral availability and cost‑effectiveness. Compared with biologic agents, it has a broader safety profile and does not require injection, but it may be less rapid in controlling severe disease. Choice of therapy depends on disease severity, patient preference and comorbidities.

Imenor should be stored at room temperature, below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed to maintain stability throughout its shelf life.

Imenor is taken orally, usually with a full glass of water. The prescribing clinician will advise whether it should be taken with food or on an empty stomach, and the exact timing relative to other medications to optimize absorption and reduce gastrointestinal irritation.

The most serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow suppression leading to life‑threatening infections, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, lung symptoms, blood counts and any signs of hypersensitivity.

Methotrexate is contraindicated in pregnant or nursing women, patients with severe renal or hepatic impairment, those with known hypersensitivity to methotrexate, and individuals receiving live vaccines. It should also be avoided in patients with uncontrolled infections or certain blood disorders without careful specialist supervision.